Skip to main content
Erschienen in: Journal of Cardiovascular Translational Research 4/2009

01.12.2009

Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?

verfasst von: Stefano Nistri, Iacopo Olivotto, Francesca Girolami, Francesca Torricelli, Franco Cecchi, Magdi H. Yacoub

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Hypertrophic cardiomyopathy (HCM) is an epidemiologically relevant, worldwide spread condition which is frequently perceived as a rare disease. This misconception might be supported by some characteristics of HCM such as its incomplete penetrance and variable age at onset and by the fact that many patients remain asymptomatic for a long course of the disease and are thus unlikely to seek for medical evaluation. Multiple evidences suggest that early diagnosis of HCM is important, not only because it allows the patients to be addressed to appropriate diagnostic work-out and to adequate therapeutical options but because it may trigger the screening of family members with the potential of further, new diagnosis of HCM in previously unsuspected individuals. Increased awareness of the disease among physicians working in community-based hospitals and in outpatients facilities, and a facilitated communication and access to tertiary referral centers, will result into a wider knowledge of the spectrum of the disease, a better access to the state-of-the-art management options for patients, and to a more diffuse practice of genetic evaluation of HCM families.
Literatur
1.
Zurück zum Zitat Adabag, A. S., Kuskowski, M. A., & Maron, B. J. (2006). Determinants for clinical diagnosis of hypertrophic cardiomyopathy. American Journal of Cardiology, 98, 1507–1511.CrossRefPubMed Adabag, A. S., Kuskowski, M. A., & Maron, B. J. (2006). Determinants for clinical diagnosis of hypertrophic cardiomyopathy. American Journal of Cardiology, 98, 1507–1511.CrossRefPubMed
2.
Zurück zum Zitat Bos, M. J., Towbin, J. A., & Ackerman, M. J. (2009). Diagnostic, prognostic, and therapeutic implications of genetic testing in hypertrophic cardiomyopathy. J Am Coll Cardiol, 54, 201–211.CrossRefPubMed Bos, M. J., Towbin, J. A., & Ackerman, M. J. (2009). Diagnostic, prognostic, and therapeutic implications of genetic testing in hypertrophic cardiomyopathy. J Am Coll Cardiol, 54, 201–211.CrossRefPubMed
3.
Zurück zum Zitat Cecchi, F., Olivotto, I., Betocchi, S., Rapezzi, C., Betocchi, S., Conte, M. G., et al. (2005). The Italian registry for hypertrophic cardiomyopathy: a nationwide survey. American Heart Journal, 150(5), 947–954.CrossRefPubMed Cecchi, F., Olivotto, I., Betocchi, S., Rapezzi, C., Betocchi, S., Conte, M. G., et al. (2005). The Italian registry for hypertrophic cardiomyopathy: a nationwide survey. American Heart Journal, 150(5), 947–954.CrossRefPubMed
4.
Zurück zum Zitat Chaitman, B. R. (2007). An electrocardiogram should not be included in routine preparticipation screening of young athletes. Circulation, 27(116), 2610–2614.CrossRef Chaitman, B. R. (2007). An electrocardiogram should not be included in routine preparticipation screening of young athletes. Circulation, 27(116), 2610–2614.CrossRef
5.
Zurück zum Zitat Charron, P., Dubourg, O., Desnos, M., et al. (1997). Diagnostic value of lectrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation, 96, 214–219.PubMed Charron, P., Dubourg, O., Desnos, M., et al. (1997). Diagnostic value of lectrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation, 96, 214–219.PubMed
6.
Zurück zum Zitat Chen-Tournoux, A., Fifer, M. A., Picard, M. H., & Hung, J. (2008). Use of tissue Doppler to distinguish discrete upper ventricular septal hypertrophy from obstructive hypertrophic cardiomyopathy. American Journal of Cardiology, 101, 1498–1503.CrossRefPubMed Chen-Tournoux, A., Fifer, M. A., Picard, M. H., & Hung, J. (2008). Use of tissue Doppler to distinguish discrete upper ventricular septal hypertrophy from obstructive hypertrophic cardiomyopathy. American Journal of Cardiology, 101, 1498–1503.CrossRefPubMed
7.
Zurück zum Zitat Codd, M. B., Sugrue, D. D., Gersh, B. J., & Melton, L. J., III. (1989). Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation, 80, 564–572.PubMed Codd, M. B., Sugrue, D. D., Gersh, B. J., & Melton, L. J., III. (1989). Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation, 80, 564–572.PubMed
8.
Zurück zum Zitat Corrado, D., Basso, C., Schiavon, M., & Thiene, G. (1998). Screening for hypertrophic cardiomyopathy in young athletes. New England Journal of Medicine, 339, 364–369.CrossRefPubMed Corrado, D., Basso, C., Schiavon, M., & Thiene, G. (1998). Screening for hypertrophic cardiomyopathy in young athletes. New England Journal of Medicine, 339, 364–369.CrossRefPubMed
9.
Zurück zum Zitat Corrado, D., Basso, C., Pavei, A., Michieli, P., Schiavon, M., & Thiene G. (2006). Trends in sudden cardiovascular death in young competitive athlete after implementation of a pre-participation screening program. Journal of the American Medical Association, 296, 1593–1601.CrossRefPubMed Corrado, D., Basso, C., Pavei, A., Michieli, P., Schiavon, M., & Thiene G. (2006). Trends in sudden cardiovascular death in young competitive athlete after implementation of a pre-participation screening program. Journal of the American Medical Association, 296, 1593–1601.CrossRefPubMed
10.
Zurück zum Zitat Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, P., et al. (2008). Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 29, 270–276.CrossRefPubMed Elliott, P., Andersson, B., Arbustini, E., Bilinska, Z., Cecchi, F., Charron, P., et al. (2008). Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 29, 270–276.CrossRefPubMed
11.
Zurück zum Zitat Girolami, F., Olivotto, I., Passerini, I., Zachara, E., Nistri, S., Re, F., et al. (2006). A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 7(8), 601–607.PubMed Girolami, F., Olivotto, I., Passerini, I., Zachara, E., Nistri, S., Re, F., et al. (2006). A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 7(8), 601–607.PubMed
12.
Zurück zum Zitat Hada, Y., Sakamoto, T., Amano, K., Yamaguci, T., Takenaka, K., Takahashi, H., et al. (1987). Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiography screening. American Journal of Cardiology, 59, 183–184.CrossRefPubMed Hada, Y., Sakamoto, T., Amano, K., Yamaguci, T., Takenaka, K., Takahashi, H., et al. (1987). Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiography screening. American Journal of Cardiology, 59, 183–184.CrossRefPubMed
13.
Zurück zum Zitat Maron, B. J., Gardin, J. M., Flack, J. M., et al. (1995). Assessment of the prevalence of hypertrophic cardiomyopathy a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation, 92, 785–789.PubMed Maron, B. J., Gardin, J. M., Flack, J. M., et al. (1995). Assessment of the prevalence of hypertrophic cardiomyopathy a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation, 92, 785–789.PubMed
14.
Zurück zum Zitat Maron, B. J., Mathenge, R., Casey, S. A., Poliac, L. C., & Longe, T. F. (1999). Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. Journal of the American College of Cardiology, 33, 1590–1595.CrossRefPubMed Maron, B. J., Mathenge, R., Casey, S. A., Poliac, L. C., & Longe, T. F. (1999). Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. Journal of the American College of Cardiology, 33, 1590–1595.CrossRefPubMed
15.
Zurück zum Zitat Maron, B. J., Spirito, P., Roman, M. J., Paranicas, M., Okin, P. M., Best, L. G., et al. (2004). Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). American Journal of Cardiology, 93, 1510–1514.CrossRefPubMed Maron, B. J., Spirito, P., Roman, M. J., Paranicas, M., Okin, P. M., Best, L. G., et al. (2004). Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). American Journal of Cardiology, 93, 1510–1514.CrossRefPubMed
16.
Zurück zum Zitat Maron, B. J. (2004). Hypertrophic cardiomyopathy: an important global disease. American Journal of Medicine, 116, 63–66.CrossRefPubMed Maron, B. J. (2004). Hypertrophic cardiomyopathy: an important global disease. American Journal of Medicine, 116, 63–66.CrossRefPubMed
17.
Zurück zum Zitat Maron, B. J., Towbin, J. A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., et al. (2006). Contemporary definitions and classifications of cardiomyopathies. An American Heart Association scientific statement from the Council of Clinical Cardiology, Heart failure and Transplantation Committee Prevention; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113, 1807–1816.CrossRefPubMed Maron, B. J., Towbin, J. A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., et al. (2006). Contemporary definitions and classifications of cardiomyopathies. An American Heart Association scientific statement from the Council of Clinical Cardiology, Heart failure and Transplantation Committee Prevention; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113, 1807–1816.CrossRefPubMed
18.
Zurück zum Zitat Maron, B. J., Haas, T. S., Doerer, J. J., Thompson, P. D., & Hodges, J. S. (2009). Comparison of U.S. and Italian Experiences with sudden cardiac deaths in young competitive athletes and implications for preparticipation screening strategies. American Journal of Cardiology, 104, 276–280.CrossRefPubMed Maron, B. J., Haas, T. S., Doerer, J. J., Thompson, P. D., & Hodges, J. S. (2009). Comparison of U.S. and Italian Experiences with sudden cardiac deaths in young competitive athletes and implications for preparticipation screening strategies. American Journal of Cardiology, 104, 276–280.CrossRefPubMed
19.
Zurück zum Zitat Maron, M. S., Maron, B. J., Harrigan, C., Buros, J., Gibson, C. M., Olivotto, I., et al. (2009). Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Journal of the American College of Cardiology, 54, 220–228.CrossRefPubMed Maron, M. S., Maron, B. J., Harrigan, C., Buros, J., Gibson, C. M., Olivotto, I., et al. (2009). Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Journal of the American College of Cardiology, 54, 220–228.CrossRefPubMed
20.
Zurück zum Zitat Morita, H., Larson, M. G., Barr, S. C., Vasan, R. S., O’Donnell, C. J., Hirschhorn, J. N., et al. (2006). Single-gene mutations and increased left ventricular wall thickness in the community. The Framingham Heart Study. Circulation, 113, 2697–2705.CrossRefPubMed Morita, H., Larson, M. G., Barr, S. C., Vasan, R. S., O’Donnell, C. J., Hirschhorn, J. N., et al. (2006). Single-gene mutations and increased left ventricular wall thickness in the community. The Framingham Heart Study. Circulation, 113, 2697–2705.CrossRefPubMed
21.
Zurück zum Zitat Myerburg, R. J., & Vetter, V. L. (2007). Electrocardiograms should be included in preparticipation screening of athletes. Circulation, 27(116), 2616–2626.CrossRef Myerburg, R. J., & Vetter, V. L. (2007). Electrocardiograms should be included in preparticipation screening of athletes. Circulation, 27(116), 2616–2626.CrossRef
22.
Zurück zum Zitat Moon, J. C., Fisher, N. G., McKenna, W. J., & Pennell, D. J. (2004). Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart, 90, 645–649.CrossRefPubMed Moon, J. C., Fisher, N. G., McKenna, W. J., & Pennell, D. J. (2004). Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart, 90, 645–649.CrossRefPubMed
23.
Zurück zum Zitat Nistri, S., Thiene, G., Basso, C., et al. (2003). Screening for hypertrophic cardiomyopathy in a young male military population. American Journal of Cardiology, 91, 1021–1023.CrossRefPubMed Nistri, S., Thiene, G., Basso, C., et al. (2003). Screening for hypertrophic cardiomyopathy in a young male military population. American Journal of Cardiology, 91, 1021–1023.CrossRefPubMed
24.
Zurück zum Zitat Olivotto, I., & Cecchi, F. (2003). The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. Italian Heart Journal, 4(9), 596–601.PubMed Olivotto, I., & Cecchi, F. (2003). The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. Italian Heart Journal, 4(9), 596–601.PubMed
25.
Zurück zum Zitat Olivotto, I., Maron, M. S., Adabag, S. A., Casey, S. A., Vargiu, D., Link, M. S., et al. (2005). Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 46, 480–487.CrossRefPubMed Olivotto, I., Maron, M. S., Adabag, S. A., Casey, S. A., Vargiu, D., Link, M. S., et al. (2005). Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 46, 480–487.CrossRefPubMed
26.
Zurück zum Zitat Olivotto, I., Girolami, F., Ackerman, M. J., Nistri, S., Bos, J. M., Zachara, E., et al. (2008). Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clinic Proceedings, 83, 630–638.CrossRefPubMed Olivotto, I., Girolami, F., Ackerman, M. J., Nistri, S., Bos, J. M., Zachara, E., et al. (2008). Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clinic Proceedings, 83, 630–638.CrossRefPubMed
27.
Zurück zum Zitat Pelliccia, A., Di Paolo, F. M., Corrado, D., et al. (2006). Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. European Heart Journal, 27, 2196–2200.CrossRefPubMed Pelliccia, A., Di Paolo, F. M., Corrado, D., et al. (2006). Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. European Heart Journal, 27, 2196–2200.CrossRefPubMed
28.
Zurück zum Zitat Rickers, C., Wilke, N. M., Jerosch-Herold, M., Casey, S. A., Panse, P., Panse, N., et al. (2005). Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation, 112, 855–861.CrossRefPubMed Rickers, C., Wilke, N. M., Jerosch-Herold, M., Casey, S. A., Panse, P., Panse, N., et al. (2005). Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation, 112, 855–861.CrossRefPubMed
29.
Zurück zum Zitat Ward, R. P., Weinert, L., Spencer, K. T., Furlong, K. T., Bednarz, J., DeCara, J., et al. (2002). Quantitative diagnosis of apical cardiomyopathy using contrast echocardiography. Journal of the American Society of Echocardiography, 15, 316–322.CrossRefPubMed Ward, R. P., Weinert, L., Spencer, K. T., Furlong, K. T., Bednarz, J., DeCara, J., et al. (2002). Quantitative diagnosis of apical cardiomyopathy using contrast echocardiography. Journal of the American Society of Echocardiography, 15, 316–322.CrossRefPubMed
30.
Zurück zum Zitat Zou, Y., Song, L., Wang, Z., Ma, A., Liu, T., Gu, H., et al. (2004). Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis in 8080 adults. American Journal of Medicine, 116, 14–18.CrossRef Zou, Y., Song, L., Wang, Z., Ma, A., Liu, T., Gu, H., et al. (2004). Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis in 8080 adults. American Journal of Medicine, 116, 14–18.CrossRef
Metadaten
Titel
Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?
verfasst von
Stefano Nistri
Iacopo Olivotto
Francesca Girolami
Francesca Torricelli
Franco Cecchi
Magdi H. Yacoub
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Journal of Cardiovascular Translational Research / Ausgabe 4/2009
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-009-9135-4

Weitere Artikel der Ausgabe 4/2009

Journal of Cardiovascular Translational Research 4/2009 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.